Joh K
Saitama Children's Medical Center, Division of Infectious Diseases and Clinical Immunology.
Nihon Rinsho. 1997 Mar;55(3):700-5.
The treatment of infection with enterohemorrhagic Escherichia coli(EHEC) aims for early prediction and prevention of severe complications such as hemolytic-uremic syndrome, encephalopathy and/or thrombotic thrombocytopenic purpura. Factors related to the complications are divided into three categories; risk factors or predisposition, predictors, and indicators of severity and outcome. Risk factors for complications include two extreme ages, infection with verotoxin 2 producing E. coli, positive stool culture for EHEC, use of antimotility drug, use of trimethoprim-sulfamethoxazole. Predictors for complications include severe abdominal pain and bloody diarrhea development of high fever, change of consciousness, urinal protein and/or occult blood, abrupt increase of white blood cell count, urinal NAG, alpha 1 microglobulin, beta 2 microglobulin, low osmolar urine, high thrombomodulin level, marked thickening of intestinal wall, increased brightness of kidney in ultrasound sonography. No preventive treatment for these complications is proven except SYNSORB-pk which is expected to effectively aborb verotoxin in the intestine.
肠出血性大肠杆菌(EHEC)感染的治疗旨在早期预测和预防诸如溶血尿毒综合征、脑病和/或血栓性血小板减少性紫癜等严重并发症。与这些并发症相关的因素分为三类:危险因素或易感性、预测指标以及严重程度和预后指标。并发症的危险因素包括两个极端年龄、感染产志贺毒素2的大肠杆菌、EHEC粪便培养阳性、使用止泻药、使用甲氧苄啶-磺胺甲恶唑。并发症的预测指标包括严重腹痛、血性腹泻、高热、意识改变、尿蛋白和/或潜血、白细胞计数突然升高、尿N-乙酰-β-D-氨基葡萄糖苷酶、α1微球蛋白、β2微球蛋白、低渗尿、高血栓调节蛋白水平、肠壁明显增厚、超声检查中肾脏亮度增加。除了有望在肠道中有效吸收志贺毒素的SYNSORB-pk外,尚无针对这些并发症的预防性治疗方法得到证实。